* Says FDA approved sNDA for Valstar
* Plans to market Valstar in H2 2009
* Shares up 5 pct
Feb 27 (Reuters) - Indevus Pharmaceuticals Inc received marketing approval from U.S. health regulators for its cancer therapy Valstar, which was withdrawn in 2002 due to impurities in the original formulation.
Shares of the company rose 5 percent after the bell.
Indevus said in a regulatory filing that it obtained approval from the U.S. Food and Drug Administration on its supplemental new drug application for Valstar.
The company, which agreed to be bought by Endo Pharmaceuticals Inc for $370 million last month, plans to market Valstar during the second half of 2009.
Valstar was approved in 1998 as a treatment for bladder cancer in patients who were not candidates for bladder removal.
Shares of the company were up at $5.35 in trading after the bell. They closed at $5.11 Friday on Nasdaq.
(Reporting by Vidya L Nathan in Bangalore; Editing by Himani Sarkar) Keywords: INDEVUS/ (vidya.loganathan@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: vidya.loganathan.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Plans to market Valstar in H2 2009
* Shares up 5 pct
Feb 27 (Reuters) - Indevus Pharmaceuticals Inc received marketing approval from U.S. health regulators for its cancer therapy Valstar, which was withdrawn in 2002 due to impurities in the original formulation.
Shares of the company rose 5 percent after the bell.
Indevus said in a regulatory filing that it obtained approval from the U.S. Food and Drug Administration on its supplemental new drug application for Valstar.
The company, which agreed to be bought by Endo Pharmaceuticals Inc for $370 million last month, plans to market Valstar during the second half of 2009.
Valstar was approved in 1998 as a treatment for bladder cancer in patients who were not candidates for bladder removal.
Shares of the company were up at $5.35 in trading after the bell. They closed at $5.11 Friday on Nasdaq.
(Reporting by Vidya L Nathan in Bangalore; Editing by Himani Sarkar) Keywords: INDEVUS/ (vidya.loganathan@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: vidya.loganathan.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.